Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) EBIT (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed EBIT for 13 consecutive years, with -$59.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 11.03% to -$59.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$300.1 million, a 39.72% increase, with the full-year FY2025 number at -$300.1 million, up 39.72% from a year prior.
  • EBIT was -$59.6 million for Q4 2025 at Madrigal Pharmaceuticals, up from -$114.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$47.2 million in Q2 2025 to a low of -$162.5 million in Q2 2024.
  • A 5-year average of -$85.7 million and a median of -$78.8 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: plummeted 94.08% in 2024, then surged 70.96% in 2025.
  • Madrigal Pharmaceuticals' EBIT stood at -$64.6 million in 2021, then plummeted by 32.04% to -$85.3 million in 2022, then crashed by 37.37% to -$117.2 million in 2023, then soared by 42.82% to -$67.0 million in 2024, then grew by 11.03% to -$59.6 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's EBIT are -$59.6 million (Q4 2025), -$114.0 million (Q3 2025), and -$47.2 million (Q2 2025).